The Swiss drug maker is the second pharmaceutical company to announce a halt to price hikes, coming after Pfizer's decision last week to reverse planned increases.
Swiss drug maker Novartis said early Wednesday it does not plan to raise prices through the end of the year, as it talks with US health officials about the Trump administration's plan to cut what consumers pay for prescription drugs.
The announcement came as part of the company’s second quarter earnings call. CEO Vasant Narasimhan said that the move was “prudent” in light of “a very dynamic environment in the United States.”
Pfizer announced last week that it would halt drug prices through the end of 2018, after CEO Ian Read spoke with President Donald Trump. Pfizer also said it would revisit price increases in 2019, to allow time for the administration to implement pieces of a blueprint, American Patients First, that includes dozens of policy ideas for reducing prices and out-of-pocket costs for patients.
Narasimhan told Reuters that while he had not spoken with Trump directly, company officials were having conversations with HHS about the blueprint and how it would affect the drug maker. Of note, the administration has said it wants to promote manufacturing of generics and biosimilar; Novartis’ generic unit, Sandoz has been under pricing pressure.
Monday was the deadline for comments on the blueprint via a formal Request for Information. The industry trade group, the Pharmaceutical Research and Manufacturers of America, issued an extensive response that called for severing the link between compensation levels for pharmacy benefit managers (PBMs) and rebates paid to them from drug companies. PBMs have been blamed for driving up the price of drugs.
Narasimhan said the pricing freeze had nothing to do with fallout over reports that the company’s previous CEO paid Trump attorney Michael Cohen $1.2 million for insights on the administration’s healthcare positions in the year after the 2016 election. Cohen is now under federal investigation in the Southern District of New York.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More